Clinical Trials Browser

OTHER × Leukemia, Myeloid, Acute × IL32 protein, human × Clear all

NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1 Suspended

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01370213 2020-05-13

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Phase 2 Completed

25 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02809092 2019-10-15

Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00274846 2017-12-28

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 2 Completed

21 enrolled 10 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

NCT00303667 2017-12-28

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Phase 1/2 Completed

50 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01106950 2017-12-28

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Phase 2 Terminated

15 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute